ESMO - Eur. Oncology

The European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology community’s work.

[ESMO - Eur. Oncology @myESMO]

The inaugural ESMO-NCCS-DukeNUS Course in Medical Oncology for Medical Students offers an immersive introduction to #MedicalOncology for fourth- and fifth-year #MedicalStudents from the Asia-Pacific.

📅 Apply by: 1 July 2026

🔗 https://t.co/cs1X2Z4L2o

[ESMO - Eur. Oncology @myESMO]

👉 Dr. Lisa Derosa calls on you to be part of the mission shaping the next generation in oncology. Join the global community at the Molecular Analysis for Precision Oncology Congress 2026 in London, 10–11 September.
⏰ Register by 8 July and save! #MAP2026 #esmomeetings

🔗 https://t.co/LCF4jPtKlv

[Annals of Oncology @Annals_Oncology]

🆕 article in press: GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults
https://t.co/BpguTUNswI

[ESMO - Eur. Oncology @myESMO]

👉 Dr. Masafumi Ikeda invites you to submit your abstract for ESMO Asia 2026, 4–6 Dec, Singapore, where biomarker‑driven innovation is transforming cancer care and shaping the future of precision oncology.

🗓 Deadline: 21 July
🔗 https://t.co/SOhfhkOFPv

#ESMOAsia26 #esmomeetings

[Annals of Oncology @Annals_Oncology]

🔥#ASCO26 Concomitant publication - BREAKWATER Cohort 3: encorafenib+cetuximab+FOLFIRI vs FOLFIRI±bevacizumab in 1L BRAF V600E-mutant mCRC
👉ORR significantly improved: 64.4% vs 39.2%
👉PFS benefit: 15.2 vs 8.3 mths; HR 0.44
👉Prolonged OS: HR 0.56, mOS not reached vs 20.3 mths

[Annals of Oncology @Annals_Oncology]

👉Manageable safety profile, no new safety signals
🎯EC+FOLFIRI is an additional 1L option & supports personalisation through flexible chemo-backbone selection
🧩Questions: maintenance, intermittent strategies, and de-intensification in frail/elderly pts.
https://t.co/Hines6J4KR

[Annals of Oncology @Annals_Oncology]

🆕 article in press: A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trial https://t.co/UGJo0sh930

[ESMO - Eur. Oncology @myESMO]

ESMO is pleased to share the results of the ESMO Presidential Elections. #ESMOElections
Florian Lordick (Germany) will serve as ESMO President 2029–2030 and join the ESMO Executive Board as President‑Elect on 1 January 2027.
🔗 https://t.co/y84ezg7zjb

[ESMO - Eur. Oncology @myESMO]

@Dr_RShatsky We look forward to welcoming you at #ESMO26 in Madrid, 16 to 20 October! https://t.co/2xQnJySbrV

[ESMO - Eur. Oncology @myESMO]

@DrYukselUrun @YJanjigianMD @curijoey @ASCO @oncodaily We look forward to welcoming you at #ESMO26 in Madrid, 16 to 20 October !

[ESMO - Eur. Oncology @myESMO]

@YJanjigianMD @curijoey @ASCO @oncodaily We look forward to welcoming you at #ESMO26 in Madrid, 16 to 20 October !

[Annals of Oncology @Annals_Oncology]

🆕 Results from the POSITIVE trial with longer term follow-up are now out in @Annals_Oncology

Temporary interruption of endocrine therapy to attempt pregnancy is safe and does not increase the risk of #breastcancer events @AnnPartridgeMD
https://t.co/vyBN0TtPyM

[Annals of Oncology @Annals_Oncology]

A retrospective analysis of SOLAR-1 shows benefit from alpelisib+fulvestrant is observed in pts with PIK3CA-mutated tumors regardless of other alterations
Greater PFS benefit was observed in pts with lower TMB & with FGFR alterations
@hoperugo @FAndreMD
https://t.co/lO0zvd66t2

[ESMO - Eur. Oncology @myESMO]

Final IMPACT results support annual PSA screening for #ProstateCancer in men with #BRCA2 mutations and highlight the value of structured screening in #BRCA1 carriers, while raising questions on refining risk-adapted #screening approaches.
#ESMODailyReporter ➡️ https://t.co/1jMvaWqMmh

[Annals of Oncology @Annals_Oncology]

🆕Now out in Annals_Oncology the @myESMO Clinical Practice Guideline for diagnosis and treatment of patients with metastatic breast cancer @E_de_Azambuja @stolaney1 @Prof_Nadia_H
https://t.co/uiQUxmOZJC

[Evandro de Azambuja, MD, PhD @E_de_Azambuja]

Glad to share this new publication! I hope it will help many oncologists and patients across the globe.
A huge thank you to all my co-authors and collaborators for their hard work, support, and dedication throughout this project.
https://t.co/9ivQRjlnLu
@myESMO
@Annals_Oncology

[ESMO - Eur. Oncology @myESMO]

@EUCouncil
@EU_Commission
@EUScienceInnov
@HorizonEU

[ESMO - Eur. Oncology @myESMO]

Diagnostics & biomarker testing are key to personalised and patient-centred #oncologycare
As discussions on #IVDR continue, ESMO is contributing recommendations to support more efficient #ClinicalResearch in Europe
🔗 https://t.co/CDfDHcAUlr

#CancerResearch #HorizonEU #ResearchImpactEU

[ESMO - Eur. Oncology @myESMO]

#ESMOMembers, one day left to cast your vote for the ESMO President 2029-2030. Your participation is important, your vote is confidential and anonymous. #ESMOElections
🔗 https://t.co/sX6DgMuPb7

[ESMO - Eur. Oncology @myESMO]

Traditional markers like PD L1, HER2, EGFR & ALK enable #PrecisionOncology but aren’t always accessible. Research now explores multimodal AI biomarkers integrating histology, molecular & clinical data.
Read more on the ESMO AI & Digital Oncology Hub 🔗 https://t.co/6GXePAYmgP